{"id":9983,"date":"2022-07-07T09:45:00","date_gmt":"2022-07-07T09:45:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/3810698_CN10698_0"},"modified":"2022-07-07T09:45:00","modified_gmt":"2022-07-07T09:45:00","slug":"zhiyi-biotech-raised-45-million-in-series-b-funding-round-to-accelerate-the-clinical-development-of-lbps-pipelines","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=9983","title":{"rendered":"Zhiyi Biotech Raised $45 Million in Series B Funding Round to Accelerate the Clinical Development of LBPs Pipelines"},"content":{"rendered":"<table name=\"logo_release\" border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/1854990\/photo_Logo.jpg?p=medium600\" border=\"0\" alt title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">GUANGZHOU, China<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">July 7, 2022<\/span><\/span> \/PRNewswire\/ &#8212; Recently, Zhiyi Biotech announced that it has raised <span class=\"xn-money\">$15 million<\/span> in its B++ funding round<i>.<\/i> The funds will be used to boost the clinical development of the company&#8217;s live biotherapeutic products (LBPs) pipelines. It&#8217;s worth mentioning that <b>Zhiyi has successfully completed a total of <\/b><b><span class=\"xn-money\">$45 Million<\/span><\/b><b>&nbsp;in B, B+ and B++ funding , <\/b>with investors including Qingkong SinoKing Capital, SDIC Venture Capital, KIP <i>etc<\/i>.<\/p>\n<p>Zhiyi is a clinical-stage biotech leading in LBPs in <span class=\"xn-location\">China<\/span>. It has built up a complete technical and industrial platform, covering from the isolation and identification of new functional strains to the development of innovative LBPs. Notably, the lead drug candidate in Zhiyi&#8217;s pipelines, SK08,&nbsp;is the first LBP developed on a unique bacterial strain <i>Bacteroides Fragilis, <\/i>and whose clinical progress is ahead of other LBPs in <span class=\"xn-location\">China<\/span>. Phase II clinical trial of SK08 carried out in <span class=\"xn-location\">China<\/span> to treat IBS-D is expected to be completed this year, and phase Ib\/II trial of SK08 combined with PD-1 inhibitor for advance solid tumor has been initiated already. Meanwhile, several products are undergoing IND filing to both FDA and NMPA. More programs are expected to enter clinical stage in the foreseeing year.<\/p>\n<p>&#8220;We are grateful to have the support and trust from our investors,&#8221; said Dr. Ye Wang, CEO of Zhiyi Biotech. <span id=\"spanHghltf638\">&#8220;<\/span>The progress in our pipeline is attributed to our team&#8217;s continuous effort and persistence in R&amp;D. Zhiyi has been always focusing on the unmet medical needs and dedicating to develop accessible drugs to benefit more patients. We are looking forward to strengthening our international collaboration with peer companies, to promote development of the whole LBPs industry.<span id=\"spanHghlt9cad\">&#8220;<\/span><\/p>\n<p><b>About Zhiyi Biotech<\/b><\/p>\n<p>Zhiyi Biotech, founded in 2013, is located in <span class=\"xn-location\">Guangzhou, China<\/span>. Its lead candidate SK08 is not only the first new strain-based LBP that entered clinical stage in <span class=\"xn-location\">China<\/span>, but also the first LBP in oncology that was approved for clinical trial by NMPA. Owning two commercial-scale facilities, Zhiyi has established a complete platform system for strain selection, <span id=\"spanHghltaee2\">druggability<\/span> study, CMC study, commercial production <i>etc.<\/i><\/p>\n<p>For more information, please visit <a href=\"https:\/\/www.zypharm.com.cn\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/www.zypharm.com.cn<\/a> or contact<span id=\"spanHghlt299c\"> <a href=\"mailto:public@zypharm.com.cn\" rel=\"nofollow\">public@zypharm.com.cn<\/a><\/span><\/p>\n<p id=\"PURL\"><img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN10698&amp;sd=2022-07-07\"> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow noopener\" href=\"https:\/\/www.prnewswire.com\/news-releases\/zhiyi-biotech-raised-45-million-in-series-b-funding-round-to-accelerate-the-clinical-development-of-lbps-pipelines-301582190.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/zhiyi-biotech-raised-45-million-in-series-b-funding-round-to-accelerate-the-clinical-development-of-lbps-pipelines-301582190.html<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>GUANGZHOU, China, July 7, 2022 \/PRNewswire\/ &#8212; Recently, Zhiyi Biotech announced that it has raised $15 million in its B++ funding round. The funds will be used to boost the clinical development of the company&#8217;s live biotherapeutic products (LBPs) pipelines. It&#8217;s worth mentioning that Zhiyi has successfully completed a total of $45 Million&nbsp;in B, B+ [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-9983","post","type-post","status-publish","format-standard","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Zhiyi Biotech Raised $45 Million in Series B Funding Round to Accelerate the Clinical Development of LBPs Pipelines - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=9983\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zhiyi Biotech Raised $45 Million in Series B Funding Round to Accelerate the Clinical Development of LBPs Pipelines - My Blog\" \/>\n<meta property=\"og:description\" content=\"GUANGZHOU, China, July 7, 2022 \/PRNewswire\/ &#8212; Recently, Zhiyi Biotech announced that it has raised $15 million in its B++ funding round. The funds will be used to boost the clinical development of the company&#8217;s live biotherapeutic products (LBPs) pipelines. It&#8217;s worth mentioning that Zhiyi has successfully completed a total of $45 Million&nbsp;in B, B+ [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=9983\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-07T09:45:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnasia.com\/media2\/1854990\/photo_Logo.jpg?p=medium600\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=9983#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=9983\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"Zhiyi Biotech Raised $45 Million in Series B Funding Round to Accelerate the Clinical Development of LBPs Pipelines\",\"datePublished\":\"2022-07-07T09:45:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=9983\"},\"wordCount\":390,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=9983#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1854990\\\/photo_Logo.jpg?p=medium600\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=9983\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=9983\",\"name\":\"Zhiyi Biotech Raised $45 Million in Series B Funding Round to Accelerate the Clinical Development of LBPs Pipelines - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=9983#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=9983#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1854990\\\/photo_Logo.jpg?p=medium600\",\"datePublished\":\"2022-07-07T09:45:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=9983#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=9983\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=9983#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1854990\\\/photo_Logo.jpg?p=medium600\",\"contentUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1854990\\\/photo_Logo.jpg?p=medium600\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=9983#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zhiyi Biotech Raised $45 Million in Series B Funding Round to Accelerate the Clinical Development of LBPs Pipelines\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zhiyi Biotech Raised $45 Million in Series B Funding Round to Accelerate the Clinical Development of LBPs Pipelines - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=9983","og_locale":"en_US","og_type":"article","og_title":"Zhiyi Biotech Raised $45 Million in Series B Funding Round to Accelerate the Clinical Development of LBPs Pipelines - My Blog","og_description":"GUANGZHOU, China, July 7, 2022 \/PRNewswire\/ &#8212; Recently, Zhiyi Biotech announced that it has raised $15 million in its B++ funding round. The funds will be used to boost the clinical development of the company&#8217;s live biotherapeutic products (LBPs) pipelines. It&#8217;s worth mentioning that Zhiyi has successfully completed a total of $45 Million&nbsp;in B, B+ [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=9983","og_site_name":"My Blog","article_published_time":"2022-07-07T09:45:00+00:00","og_image":[{"url":"https:\/\/mma.prnasia.com\/media2\/1854990\/photo_Logo.jpg?p=medium600","type":"","width":"","height":""}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=9983#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=9983"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"Zhiyi Biotech Raised $45 Million in Series B Funding Round to Accelerate the Clinical Development of LBPs Pipelines","datePublished":"2022-07-07T09:45:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=9983"},"wordCount":390,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=9983#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/1854990\/photo_Logo.jpg?p=medium600","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=9983","url":"https:\/\/transmediavictoria.net.au\/?p=9983","name":"Zhiyi Biotech Raised $45 Million in Series B Funding Round to Accelerate the Clinical Development of LBPs Pipelines - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=9983#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=9983#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/1854990\/photo_Logo.jpg?p=medium600","datePublished":"2022-07-07T09:45:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=9983#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=9983"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=9983#primaryimage","url":"https:\/\/mma.prnasia.com\/media2\/1854990\/photo_Logo.jpg?p=medium600","contentUrl":"https:\/\/mma.prnasia.com\/media2\/1854990\/photo_Logo.jpg?p=medium600"},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=9983#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"Zhiyi Biotech Raised $45 Million in Series B Funding Round to Accelerate the Clinical Development of LBPs Pipelines"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/9983","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=9983"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/9983\/revisions"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=9983"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=9983"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=9983"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}